-
1.发明申请POLYMERIC SORBENT FOR REMOVAL OF IMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS 审中-公开用于从全血和血液制品中清除污染物的聚合物溶液
公开(公告)号：WO2013025483A3
公开(公告)日：2014-05-22
申请号：PCT/US2012050295
申请日：2012-08-10
Applicant: CYTOSORBENTS CORP , CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
CPC classification number: A01N1/021 , B01J20/267 , B01J20/28016 , B01J20/28073 , B01J20/28076 , B01J20/2808 , B01J20/28083 , B01J20/28085 , C08F236/20
Abstract: The invention concerns methods of treating stored blood and blood products maximizing shelf life and/or minimizing transfusion related complications such as non¬ hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood and blood products milieu through use of a sorbent.
Abstract translation: 本发明涉及治疗储存血液和血液制品的方法，其最大化保质期和/或最小化输血相关并发症，例如非溶血性输血反应，例如发烧，输血相关急性肺损伤（TRALI），输血相关性呼吸困难（TAD）和 通过使用吸附剂去除血液和血液制品环境中的不合需要的分子来进行过敏反应。
-
2.发明申请USE OF GASTROINTESTINALLY ADMINISTERED POROUS ENTERON SORBENT POLYMERS TO PREVENT OR TREAT RADIATION INDUCED MUCOSITIS, ESOPHAGITIS, ENTERITIS, COLITIS, AND GASTROINTESTINAL ACUTE RADIATION SYNDROME 审中-公开使用胃肠道输注多孔分子聚合物预防或治疗辐射诱发的神经细胞，ESOPHAGITIS，EnterITIS，COLITIS和GASTROINTESTINAL急性放射综合征
公开(公告)号：WO2016054458A8
公开(公告)日：2016-05-26
申请号：PCT/US2015053622
申请日：2015-10-02
Applicant: CYTOSORBENTS CORP
Inventor： ALI HUMAYRA BEGUM , GOLOBISH THOMAS D , CAPPONI VINCENT J , CHAN PHILLIP P , YOUNG WEI-TAI , SCHEIRER ANDREW ROBERT
IPC: A61K31/74 , A61K31/745 , A61K31/75 , C08F236/20
CPC classification number: A61K31/765 , A61K9/0053 , A61K31/75 , A61K31/755 , C08F236/20
Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
Abstract translation: 本文公开了使用一种或多种肠胃吸入剂聚合物（例如口服，口服，肠胃，肠胃，肠胃，肠道，肠道，肠道，肠道， 通过进食或胃管，通过造口或直肠）。
-
公开(公告)号：WO2014005039A2
公开(公告)日：2014-01-03
申请号：PCT/US2013048615
申请日：2013-06-28
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
IPC: A61M1/34
CPC classification number: A61M1/3679 , A61K9/16 , A61K31/765 , A61M2202/0057 , A61M2202/0405 , A61M2202/0413 , A61M2202/0415 , A61M2202/0423 , A61M2202/0464 , A61M2202/0466 , A61M2202/049 , A61M2202/0492 , A61M2202/0496 , A61M2202/20 , A61M2202/203 , A61M2202/206 , B01J20/261 , B01J20/28069 , B01J20/28078 , C08F299/00 , C08J9/26 , C08J2201/0444 , C08J2207/10 , C08J2353/00
Abstract: Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50Å to 40,000Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50Å to 40,000Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same.
Abstract translation: 本文提供的是减少生物物质中的污染物或通过一种或多种毒素治疗受试者污染物的材料和方法，包括使生物物质与有效量的能够吸附毒素的吸附剂接触，其中吸附剂包括多个孔 范围为50至40,000埃，孔体积为0.5cc / g至5.0cc / g，尺寸为0.05mm至2cm，并吸附毒素。 还提供了用于减少包含能够吸附毒素的吸附剂的生物物质中的一种或多种毒素污染的试剂盒，其中吸附剂包括多孔孔隙范围为50至40,000埃，孔体积为0.5cc / g至5.0 cc / g和0.05mm至2cm的尺寸，以及当不与其包装一起使用时存储所述吸附剂的容器。
-
4.发明公开POLYMERIC SORBENT FOR REMOVAL OF IMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS 审中-公开POLYMERES SORPTIONSMITTEL ZUR ENTFERNUNG VON VERUNREINIGUNGEN AUS VOLLBLUT UND BLUTPRODUKTEN
公开(公告)号：EP2665358A4
公开(公告)日：2014-06-25
申请号：EP12732231
申请日：2012-01-06
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
CPC classification number: A01N1/0263 , A01N1/0278 , B01J20/267 , B01J20/28004 , B01J20/28069 , B01J20/28078 , B01J20/3208 , B01J20/327 , B01J20/3272 , B01J20/328 , Y10T29/49826 , Y10T428/2982
Abstract: The invention concerns methods of treating blood, blood products or physiologic fluid to maximize shelf life and/or minimizing transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood, blood product or physiologic fluid milieu through use of a sorbent.
Abstract translation: 本发明涉及治疗血液，血液制品或生理液体以最大化保质期和/或最小化输血相关并发症的方法，例如非溶血性输血反应，例如发烧，输血相关急性肺损伤（TRALI），输血相关呼吸困难（TAD） ），以及通过使用吸附剂去除血液，血液制品或生理液体环境中不需要的分子的过敏反应。
-
公开(公告)号：EP3200805A4
公开(公告)日：2018-07-11
申请号：EP15847021
申请日：2015-10-02
Applicant: CYTOSORBENTS CORP
Inventor： ALI HUMAYRA BEGUM , GOLOBISH THOMAS D , CAPPONI VINCENT J , CHAN PHILLIP P , YOUNG WEI-TAI , SCHEIRER ANDREW ROBERT
CPC classification number: A61K31/765 , A61K9/0053 , A61K31/75 , A61K31/79 , A61P1/00 , A61P1/04 , A61P1/06
Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).
-
Patent Agency Ranking6.发明公开POLYMERIC SORBENT FOR REMOVAL OF IMPURITIES FROM WHOLE BLOOD AND BLOOD PRODUCTS 审中-公开聚合物吸附剂FOR污染从全血和产物的清除
公开(公告)号：EP2741605A4
公开(公告)日：2015-06-10
申请号：EP12824141
申请日：2012-08-10
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
CPC classification number: A01N1/021 , B01J20/267 , B01J20/28016 , B01J20/28073 , B01J20/28076 , B01J20/2808 , B01J20/28083 , B01J20/28085 , C08F236/20
Abstract: The invention concerns methods of treating stored blood and blood products maximizing shelf life and/or minimizing transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood and blood products milieu through use of a sorbent.
-
公开(公告)号：CA2844688C
公开(公告)日：2021-10-19
申请号：CA2844688
申请日：2012-08-10
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
Abstract: The invention concerns methods of treating stored blood and blood products maximizing shelf life and/or minimizing transfusion related complications such as non¬ hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood and blood products milieu through use of a sorbent.
-
公开(公告)号：AU2012295350A1
公开(公告)日：2014-03-06
申请号：AU2012295350
申请日：2012-08-10
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
Abstract: The invention concerns methods of treating stored blood and blood products maximizing shelf life and/or minimizing transfusion related complications such as non¬ hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood and blood products milieu through use of a sorbent.
-
公开(公告)号：AU2012204271A1
公开(公告)日：2013-07-18
申请号：AU2012204271
申请日：2012-01-06
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
Abstract: Methods of treating blood, blood products or physiologic fluid maximize shelf life and/or minimize transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood, blood product or physiologic fluid milieu through use of a sorbent. The blood purification devices comprise: (a) a compliant container suitable for the storage of blood, blood product or physiologic fluid; (b) sorbent comprising hemocompatible material suitable for treating blood, blood product or physiologic fluid, the sorbent performing at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood product or physiologic fluid; where the sorbent is contained within the compliant container.
-
公开(公告)号：CA2823953A1
公开(公告)日：2012-07-12
申请号：CA2823953
申请日：2012-01-06
Applicant: CYTOSORBENTS CORP
Inventor： CHAN PHILLIP P , CAPPONI VINCENT J , GOLOBISH THOMAS D , ALI HUMAYRA BEGUM
Abstract: Methods of treating blood, blood products or physiologic fluid maximize shelf life and/or minimize transfusion related complications such as non-hemolytic transfusion reactions such as fever, transfusion-related acute lung injury (TRALI), transfusion associated dyspnea (TAD), and allergic reactions by removing undesirable molecules in the blood, blood product or physiologic fluid milieu through use of a sorbent. The blood purification devices comprise: (a) a compliant container suitable for the storage of blood, blood product or physiologic fluid; (b) sorbent comprising hemocompatible material suitable for treating blood, blood product or physiologic fluid, the sorbent performing at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood product or physiologic fluid; where the sorbent is contained within the compliant container.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.037 seconds)
